Month

Your search for 04/2015 returned 35 results.


EASL 2015 Hepatitis Abstract Choices: Dr. Ploss

For more information on the selected EASL 2015 Hepatitis abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G09 Targeting a Host-Cell Entry Factor Barricades Antiviral Resistant HCV Variants From On-Therapy Breakthrough In Human-Liver Mice Vercauteren K et al. ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Gaglio

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Abstract G15 The Association of Sofosbuvir and Daclatasvir For Treating Severe Recurrence of HCV Infection After Liver Transplantation: Results From a Large French ...

Read More


EASL 2015 HCV Abstract Choices: Dr. Lebovics

For more information on the selected EASL 2015 HCV abstracts below and others to be presented at The International Liver Congress™, please click here to review the Congress abstract e-book. Current agents in special populations Abstract G02 Ledipasvir/Sofosbuvir with Ribavirin is Safe And Efficacious in Decompensated and Post Liver Transplantation Patients ...

Read More


Effective HCV therapy in HIV coinfected patients

PHOTON-2 study results confirm the findings of PHOTON-1: sofosbuvir and ribavirin provide high rates of sustained virological response in patients with HCV genotypes 1–3 who are co-infected with HIV. PHOTON-2 also provides the first clinical evidence that an interferon-free regimen can be highly effective for treatment of HCV genotype 4 in patients co-infected ...

Read More


Successful HCV virus eradication is durable

Study reconfirms that successful anti-HCV therapy translates into increased patient survival at least in chronically infected patients with advanced stages of fibrosis. Achieving SVR did not entirely prevent hepatic decompensation or HCC, which adds further credence to continued long-term surveillance for HCC in SVR patients. Long-term complications of chronic ...

Read More


Treatment-induced SVR is a long-term HCV cure

Study indicates that a treatment-induced SVR corresponds to a cure for Hepatitis C, and that the clinical significance of any residual trace amounts of HCV RNA seems limited A sustained viral response (SVR), defined as undetectable HCV RNA in serum 24 weeks after the end of treatment, is regarded as a cure from HCV infection. However, it has been hypothesized that ...

Read More


6-week Hepatitis C DAA drug regimen is effective

A simple 6-week course of three direct-acting antiviral drugs appears to be effective and well tolerated in patients with chronic HCV genotype 1 infection without cirrhosis Simple hepatitis C treatment regimens with a short duration, low pill burdens, and few adverse effects could improve patient adherence, which is vital considering that the ultimate goal is to ...

Read More


Urgent need for birth cohort hepatitis C testing

Study highlights urgent need to implement recent CDC and USPTF birth cohort Hepatitis C testing recommendations in the routine clinical environment While there have been many recent notable advances in the treatment of hepatitis C, these advances can only help those individuals who are tested and identified. Unfortunately, the proportion of unidentified anti-HCV ...

Read More


HIV HCV coinfection: Reasons for HCV Tx failure

New study suggests that HCV reinfection is not the reason for HCV treatment failure in sexually active HIV-infected patients with acute HCV HIV-infected patients with acute HCV (HIV HCV coinfection) are likely to be at high risk of reexposure and therefore the presence of switching genotype or viral rebound following HCV therapy, indicating treatment failure, is ...

Read More


HCV therapy access reduces HCV-related deaths

A global reduction of HCV liver-related mortality is dependent on access to therapy Between 64 and 103 million individuals worldwide are estimated to be chronically infected with hepatitis C (HCV). Fortunately, with the advent of interferon-free therapy with SVR rates in pivotal phase 2 and 3 trials of between 92% and 100%, it’s possible to cure chronic HCV ...

Read More